184 related articles for article (PubMed ID: 36919196)
1. Review article: An analysis of the pharmacological rationale for selecting drugs to inhibit vomiting or increase gastric emptying during treatment of gastroparesis.
Sanger GJ; Andrews PLR
Aliment Pharmacol Ther; 2023 May; 57(9):962-978. PubMed ID: 36919196
[TBL] [Abstract][Full Text] [Related]
2. Investigational drug therapies for the treatment of gastroparesis.
Sanger GJ; Pasricha PJ
Expert Opin Investig Drugs; 2017 Mar; 26(3):331-342. PubMed ID: 28127997
[TBL] [Abstract][Full Text] [Related]
3. The relationship between gastric motility and nausea: gastric prokinetic agents as treatments.
Sanger GJ; Broad J; Andrews PL
Eur J Pharmacol; 2013 Sep; 715(1-3):10-4. PubMed ID: 23831391
[TBL] [Abstract][Full Text] [Related]
4. Drugs acting at 5-HT4 , D2 , motilin, and ghrelin receptors differ markedly in how they affect neuromuscular functions in human isolated stomach.
Broad J; Góralczyk A; Mannur K; Dukes GE; Sanger GJ
Neurogastroenterol Motil; 2014 Jun; 26(6):851-61. PubMed ID: 24750304
[TBL] [Abstract][Full Text] [Related]
5. Novel approaches to the treatment of nausea and vomiting.
Ladabaum U; Hasler WL
Dig Dis; 1999; 17(3):125-32. PubMed ID: 10697661
[TBL] [Abstract][Full Text] [Related]
6. Gastric electrical stimulation: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(16):1-79. PubMed ID: 23074486
[TBL] [Abstract][Full Text] [Related]
7. Current treatment of nausea and vomiting associated with gastroparesis: antiemetics, prokinetics, tricyclics.
Stapleton J; Wo JM
Gastrointest Endosc Clin N Am; 2009 Jan; 19(1):57-72, vi. PubMed ID: 19232281
[TBL] [Abstract][Full Text] [Related]
8. Gastroparesis-associated refractory nausea treated with aprepitant.
Fahler J; Wall GC; Leman BI
Ann Pharmacother; 2012 Dec; 46(12):e38. PubMed ID: 23191934
[TBL] [Abstract][Full Text] [Related]
9. Rapid improvement in post-infectious gastroparesis symptoms with mirtazapine.
Kundu S; Rogal S; Alam A; Levinthal DJ
World J Gastroenterol; 2014 Jun; 20(21):6671-4. PubMed ID: 24914393
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for the treatment of gastroparesis.
Hasler WL
Expert Opin Emerg Drugs; 2014 Jun; 19(2):261-79. PubMed ID: 24669936
[TBL] [Abstract][Full Text] [Related]
11. A case report of prucalopride treatment in pediatric gastroparesis: a novel therapy.
Escobar-Serna DP; Peralta-Palmezano FJ; Peralta-Palmezano JJ
Arch Argent Pediatr; 2022 Apr; 120(2):e98-e101. PubMed ID: 35338825
[TBL] [Abstract][Full Text] [Related]
12. Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis.
Lembo A; Camilleri M; McCallum R; Sastre R; Breton C; Spence S; White J; Currie M; Gottesdiener K; Stoner E;
Gastroenterology; 2016 Jul; 151(1):87-96.e6. PubMed ID: 27055601
[TBL] [Abstract][Full Text] [Related]
13. Review article: The diagnosis and management of gastroparesis.
Haans JJ; Masclee AA
Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():37-46. PubMed ID: 18081647
[TBL] [Abstract][Full Text] [Related]
14. Prucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study.
Carbone F; Van den Houte K; Clevers E; Andrews CN; Papathanasopoulos A; Holvoet L; Van Oudenhove L; Caenepeel P; Arts J; Vanuytsel T; Tack J
Am J Gastroenterol; 2019 Aug; 114(8):1265-1274. PubMed ID: 31295161
[TBL] [Abstract][Full Text] [Related]
15. Prucalopride in diabetic and connective tissue disease-related gastroparesis: Randomized placebo-controlled crossover pilot trial.
Andrews CN; Woo M; Buresi M; Curley M; Gupta M; Tack J; Wilsack L; Nasser Y
Neurogastroenterol Motil; 2021 Jan; 33(1):e13958. PubMed ID: 32743954
[TBL] [Abstract][Full Text] [Related]
16. Randomized clinical trial: a controlled pilot trial of the 5-HT4 receptor agonist revexepride in patients with symptoms suggestive of gastroparesis.
Tack J; Rotondo A; Meulemans A; Thielemans L; Cools M
Neurogastroenterol Motil; 2016 Apr; 28(4):487-97. PubMed ID: 27010235
[TBL] [Abstract][Full Text] [Related]
17. Anti-emetic and emetic effects of erythromycin in Suncus murinus: role of vagal nerve activation, gastric motility stimulation and motilin receptors.
Javid FA; Bulmer DC; Broad J; Aziz Q; Dukes GE; Sanger GJ
Eur J Pharmacol; 2013 Jan; 699(1-3):48-54. PubMed ID: 23201066
[TBL] [Abstract][Full Text] [Related]
18. Ghrelin and motilin receptors as drug targets for gastrointestinal disorders.
Sanger GJ; Furness JB
Nat Rev Gastroenterol Hepatol; 2016 Jan; 13(1):38-48. PubMed ID: 26392067
[TBL] [Abstract][Full Text] [Related]
19. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis.
Schol J; Wauters L; Dickman R; Drug V; Mulak A; Serra J; Enck P; Tack J;
United European Gastroenterol J; 2021 Apr; 9(3):287-306. PubMed ID: 33939892
[TBL] [Abstract][Full Text] [Related]
20. EM574, an erythromycin derivative, improves delayed gastric emptying of semi-solid meals in conscious dogs.
Sato F; Marui S; Inatomi N; Itoh Z; Omura S
Eur J Pharmacol; 2000 Apr; 395(2):165-72. PubMed ID: 10794824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
